ATE398125T1 - Chinazolin-derivate als tgf-beta-inhibitoren - Google Patents

Chinazolin-derivate als tgf-beta-inhibitoren

Info

Publication number: ATE398125T1
Authority: AT; Austria
Prior art keywords: tgf beta; quinazoline derivatives; beta inhibitors; mediated disease; tgf
Prior art date: 2003-03-12

Application number

AT04718542T

Other languages

English (en)

Inventor

Robert Scarborough

Anjali Pandey

Meenakshi Venkatraman

Original Assignee

Millennium Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-12

Filing date

2004-03-08

Publication date

2008-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32990876&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE398125(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-03-08 Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc

2008-07-15 Application granted granted Critical

2008-07-15 Publication of ATE398125T1 publication Critical patent/ATE398125T1/de

Links

239000003112 inhibitor Substances 0.000 title 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
125000001931 aliphatic group Chemical group 0.000 abstract 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 1
125000001624 naphthyl group Chemical group 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT04718542T 2003-03-12 2004-03-08 Chinazolin-derivate als tgf-beta-inhibitoren ATE398125T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US45416403P	2003-03-12	2003-03-12

Publications (1)

Publication Number	Publication Date
ATE398125T1 true ATE398125T1 (de)	2008-07-15

Family

ID=32990876

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04718542T ATE398125T1 (de)	2003-03-12	2004-03-08	Chinazolin-derivate als tgf-beta-inhibitoren

Country Status (6)

Country	Link
US (2)	US7189733B2 (de)
EP (1)	EP1603908B1 (de)
AT (1)	ATE398125T1 (de)
DE (1)	DE602004014347D1 (de)
ES (1)	ES2305744T3 (de)
WO (1)	WO2004081009A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030125344A1 (en) *	2001-03-23	2003-07-03	Bayer Corporation	Rho-kinase inhibitors
DE60218138T2 (de) *	2001-03-23	2007-09-20	Bayer Pharmaceuticals Corp., West Haven	Rho-kinase inhibitoren
CL2004000409A1 (es) *	2003-03-03	2005-01-07	Vertex Pharma	Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
CA2520323C (en) *	2003-04-09	2013-07-09	Exelixis, Inc.	Tie-2 modulators and methods of use
US7718658B2 (en) *	2004-09-02	2010-05-18	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
US8283354B2 (en) *	2004-09-02	2012-10-09	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
US7928107B2 (en) *	2004-09-02	2011-04-19	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
MX2007007446A (es) *	2004-12-17	2008-01-14	Vertex Pharma	Procesos para la produccion de 4-aminoquinazolinas.
US7683066B2 (en)	2005-05-20	2010-03-23	Vertex Pharmaceuticals Incorporated	Isoquinolines useful as modulators of ion channels
KR101129868B1 (ko)	2006-10-04	2012-04-12	화이자 프로덕츠 인코포레이티드	칼슘 수용체 길항제로서의 피리도［4,3-ｄ］피리미딘-4(3Ｈ)-온 유도체
AR070127A1 (es) *	2008-01-11	2010-03-17	Novartis Ag	Pirrolo - pirimidinas y pirrolo -piridinas
WO2009146301A1 (en) *	2008-05-27	2009-12-03	Yale University	TARGETING TGF-β AS A THERAPY FOR ALZHEIMER'S DISEASE
EP2285380A4 (de) *	2008-05-30	2012-03-14	Summa Health Systems Llc	Verfahren zur verwendung von tgf-b-rezeptor-hemmern oder der aktivin-like-kinase (alk)-5-hemmer a-83-01 und sb-431542 zur behandlung von augenerkrankungen und wundheilungsleiden
US20100267731A1 (en) *	2009-04-17	2010-10-21	Summa Health Systems, LLC	Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
EA201200653A1 (ru)	2009-11-07	2013-01-30	Мерк Патент Гмбх	Гетариламинохинолины
EP2531500B1 (de) *	2010-02-05	2018-01-24	Merck Patent GmbH	Hetaryl-[1,8]naphthyridinderivate
TW201210597A (en) *	2010-06-09	2012-03-16	Gilead Sciences Inc	Inhibitors of hepatitis C virus
EA201300052A1 (ru) *	2010-06-28	2013-06-28	Мерк Патент Гмбх	[1,8]нафтиридиновые производные
KR20140022829A (ko) *	2011-03-09	2014-02-25	메르크 파텐트 게엠베하	피리도 [2, 3 - ｂ] 피라진 유도체 및 그 치료적 용도
WO2014058317A1 (en)	2012-10-10	2014-04-17	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Methods and means for predicting resistance to anti-cancer treatment
RS60371B1 (sr)	2013-03-14	2020-07-31	Brigham & Womens Hospital Inc	Sastavi i postupci za ekspanziju i kultivisanje epitelnih matičnih ćelija
KR101658111B1 (ko) *	2013-05-13	2016-09-20	제일모직 주식회사	유기광전자소자용 화합물, 이를 포함하는 유기발광소자 및 상기 유기발광소자를 포함하는 표시장치
CN103570632B (zh) *	2013-07-22	2015-09-30	成都理工大学	无催化剂的4(3h)-喹唑啉酮的合成方法
LT3089971T (lt)	2014-01-01	2020-10-12	Medivation Technologies Llc	Junginiai ir panaudojimo būdai
CA2959404A1 (en)	2014-09-03	2016-03-10	The Brigham And Women's Hospital, Inc.	Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
EP3206689B1 (de)	2014-10-14	2021-12-08	La Jolla Institute of Allergy & Immunology	Inhibitoren von niedermolekularer protein-tyrosinphosphatase und verwendungen davon
EP3313420B1 (de)	2015-06-25	2024-03-13	The Children's Medical Center Corporation	Verfahren und zusammensetzungen in bezug auf hämatopoetische stammzellenexpansion, -anreicherung und -pflege
CN108137597A (zh) *	2015-07-28	2018-06-08	百时美施贵宝公司	TGFβ受体拮抗剂
JP2019506153A (ja)	2016-01-08	2019-03-07	マサチューセッツインスティテュートオブテクノロジー	分化した腸内分泌細胞およびインスリン産生細胞の作製
US11583593B2 (en)	2016-01-14	2023-02-21	Synthis Therapeutics, Inc.	Antibody-ALK5 inhibitor conjugates and their uses
US11260130B2 (en)	2016-03-02	2022-03-01	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en)	2016-03-02	2019-02-26	Frequency Therapeutics, Inc.	Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en)	2016-03-02	2019-02-12	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US20190119642A1 (en)	2016-03-15	2019-04-25	Children's Medical Center Corporation	Methods and compositions relating to hematopoietic stem cell expansion
WO2018125746A1 (en)	2016-12-30	2018-07-05	Frequency Therapeutics, Inc.	1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
US11066420B2 (en)	2017-05-01	2021-07-20	Sanford Burnham Prebys Medical Discovery Institute	Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
CN109096254B (zh) *	2017-06-20	2021-07-06	江西师范大学	喹唑啉衍生物及其制备方法和应用
CN112135613A (zh)	2018-03-20	2020-12-25	西奈山伊坎医学院	激酶抑制剂化合物和组合物及使用方法
US20210254006A1 (en)	2018-06-06	2021-08-19	Ideaya Biosciences, Inc.	Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
CN113195707A (zh)	2018-08-17	2021-07-30	频率治疗公司	用于通过上调jag-1来生成毛细胞的组合物和方法
US11617745B2 (en)	2018-08-17	2023-04-04	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by downregulating FOXO
AU2019419414A1 (en)	2018-12-31	2023-04-06	Icahn School Of Medicine At Mount Sinai	Kinase inhibitor compounds and compositions and methods of use
EP4313967B1 (de)	2021-03-29	2025-11-12	Gilead Sciences, Inc.	Khk-hemmer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5776963A (en) *	1989-05-19	1998-07-07	Hoechst Marion Roussel, Inc.	3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5223501A (en) *	1991-05-10	1993-06-29	Merck & Co., Inc.	Substituted pyrimidinones bearing acidic functional groups as angiotensin ii antagonists
US6225318B1 (en) *	1996-10-17	2001-05-01	Pfizer Inc	4-aminoquinazolone derivatives
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
US20040038856A1 (en)	2002-05-17	2004-02-26	Sarvajit Chakravarty	Treatment of fibroproliferative disorders using TGF-beta inhibitors
CA2494367A1 (en)	2002-07-25	2004-02-05	Scios Inc.	Methods for improvement of lung function using tgf-.beta. inhibitors

2004
- 2004-03-08 AT AT04718542T patent/ATE398125T1/de not_active IP Right Cessation
- 2004-03-08 WO PCT/US2004/007090 patent/WO2004081009A1/en not_active Ceased
- 2004-03-08 DE DE602004014347T patent/DE602004014347D1/de not_active Expired - Lifetime
- 2004-03-08 EP EP04718542A patent/EP1603908B1/de not_active Expired - Lifetime
- 2004-03-08 ES ES04718542T patent/ES2305744T3/es not_active Expired - Lifetime
- 2004-03-08 US US10/795,538 patent/US7189733B2/en not_active Expired - Fee Related
2007
- 2007-01-16 US US11/653,679 patent/US8268857B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE602004014347D1 (de)	2008-07-24
ES2305744T3 (es)	2008-11-01
US7189733B2 (en)	2007-03-13
US8268857B2 (en)	2012-09-18
EP1603908A1 (de)	2005-12-14
WO2004081009A1 (en)	2004-09-23
US20070142408A1 (en)	2007-06-21
US20040204431A1 (en)	2004-10-14
EP1603908B1 (de)	2008-06-11

Publication	Publication Date	Title
ATE398125T1 (de)	2008-07-15	Chinazolin-derivate als tgf-beta-inhibitoren
UA87153C2 (ru)	2009-06-25	Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
DK1767535T3 (da)	2010-04-12	Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
ATE433447T1 (de)	2009-06-15	Pyrimiidinverbindungen
EA200600317A1 (ru)	2006-06-30	Производные омега-карбоксиарилдифенилмочевины (варианты), фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с их использованием (варианты)
CY1107301T1 (el)	2012-11-21	Ιμιδαζο και θειαζολοπυριδινες ως αναστολεις κινασης jak3
DE60315677D1 (de)	2007-09-27	Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
CY1109998T1 (el)	2014-09-10	Ενδυναμωτες υποδοχεων γλουταμινικου
CY1119077T1 (el)	2018-01-10	Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων
BRPI0510177B8 (pt)	2021-05-25	composto, composição farmacêutica e uso do mesmo
NO20063479L (no)	2006-10-02	Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
CY1107403T1 (el)	2012-12-19	Μια μεθοδος δια την παρασκευη υπερινδοπριλης,των αναλογων ενωσεων αυτης και των αλατων αυτων με χρησιμοποιηση ενδιαμεσων ενωσεων 2,5-διοξο-οξαζολιδινης
NO20044526L (no)	2004-12-21	Hemisterlinderivater og anvendelser derav
ATE346067T1 (de)	2006-12-15	Carbolinderivate
EA200700202A1 (ru)	2007-10-26	Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
MA32956B1 (fr)	2012-01-02	Derives de 5-amino-2-(1-hydroxyethyl)-tetrahydropyrane
NO20043016L (no)	2004-07-15	6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
ES2186550B2 (es)	2003-11-16	Nuevos derivados de oxazolidinonas como antibacterianos.
EA200501584A1 (ru)	2006-06-30	Бета-карболины, применяемые для лечения воспалительных заболеваний
ATE399168T1 (de)	2008-07-15	Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
ATE441630T1 (de)	2009-09-15	Substituierte cyclopenten-verbindungen
NO20044548L (no)	2004-11-26	Fremgangsmate for fremstilling av 6-alkaliden-penemderivater
ATE543803T1 (de)	2012-02-15	3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
DE602005011267D1 (de)	2009-01-08	Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
CO5540311A2 (es)	2005-07-29	Derivados de pirimidina utiles como inhibidores de cox-2 selectivos

Legal Events

Date	Code	Title	Description
2008-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties